L-arginine/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases necrotising enterocolitis incidence
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×2“L-arginine had a 59% reduction in the incidence of stage II and III NEC (RR 0.41, 95% CI 0.20 to 0.85, NNT = 9) compared with placebo (P = 0.02).”
Quoted verbatim from Arginine supplementation in prevention of necrotizing enterocolitis in the premature infant: an updated systematic review.. - Study
- meta-analysis
- Population
- preterm infants born at 34 weeks gestation or less with birth weight 1500 g or less; event definition is stage II and III NEC
Arginine supplementation in prevention of necrotizing enterocolitis in the premature infant: an updated systematic review.2014PMID:25205007Permalink
Keep reading
- Everything the graph holds on L-arginine
- Every compound studied against Necrotising enterocolitis incidence
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M0EVBPJWYW9ZF5ESYH4GM0Y5